"10.1371_journal.pone.0054014","plos one","2013-03-14T00:00:00Z","Manish A Shah; Zev A Wainberg; Daniel V T Catenacci; Howard S Hochster; James Ford; Pamela Kunz; Fa-Chyi Lee; Howard Kallender; Fabiola Cecchi; Daniel C Rabe; Harold Keer; Anne-Marie Martin; Yuan Liu; Robert Gagnon; Peter Bonate; Li Liu; Tona Gilmer; Donald P Bottaro","The Weill Cornell Medical College/New Yorkâ€Presbyterian Hospital, New York, New York, United States of America; University of California Los Angeles, Los Angeles, California, United States of America; University of Chicago, Chicago, Illinois, United States of America; Yale University, New Haven, Connecticut, United States of America; Stanford University, Stanford, California, United States of America; University of New Mexico, Albuquerque, New Mexico, United States of America; GlaxoSmithKline, Collegeville, Pennsylvania, United States of America; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America; Exelixis, South San Francisco, California, United States of America; GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America","Final approval of manuscript: MAS ZAW DC HH JF PK FCL H. Kallender FC DCR H. Keer AMM YL RG PB LL TG DPB. Conceived and designed the experiments: H. Kallender MAS DPB H. Keer. Performed the experiments: MAS ZAW DC HH JF PK FCL DPB PB LL TG. Analyzed the data: DPB DCR FC MAS H. Kallender AMM YL RG PB LL TG. Contributed reagents/materials/analysis tools: DPB H. Kallender MAS. Wrote the paper: MAS H. Kallender DPB.","Dr. Kallender, Dr. Martin, Dr. Y. Liu, Dr. Gagnon Dr. L. Liu, Dr. Gilmer are employees of, and have equity interest in GlaxoSmithKline. Dr. Keer is an employee of FivePrime Therapeutics Inc. with equity interest in Exelixis. Editorial support in the form of development of draft outline, development of manuscript first draft, assembling tables and figures, collating author comments, copyediting and referencing was provided by Ann Sherwood, PhD of CONNEXION Healthcare, Newtown, PA, and by MediTech Media, Manchester, UK, and was funded by GlaxoSmithKline. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","03","Manish A Shah","MAS",18,TRUE,1,11,5,2,TRUE,TRUE,TRUE,3,"12;13;14",TRUE
